

Fisher Broyles

Name: Rita Wu, PhD

Email: rita.wu@fisherbroyles.com

Direct: +1.720.316.3624

Office: Denver

Practice Areas: Intellectual Property

Bar Admissions: USPTO; New York; Colorado

Education: Fordham School of Law, JD; University of Arizona, BS in Molecular and Cellular Biology, Ph.D. in Microbiology and Immunology

Experience: Arnold and Porter, LLP; King and Spalding, LLP; Dorsey and Whitney, LLP

Dr. Rita Wu blends her academic background with fifteen years of experience in intellectual property law. With an education that includes a PhD in microbiology and immunology as well as clinical research experience as a post-doctoral fellow studying cancer immunotherapies at Weill Medical College of Cornell University, Rita brings a wide range of technical expertise to her patent law practice.

Rita focuses on patent issues and is a trusted advisor to life science, agricultural, pharmaceutical, and medical device companies nationwide. Her practice encompasses strategic patent preparation, prosecution and related counseling.

Rita works closely with her clients to develop and maintain a sophisticated and global patent portfolio that is commercially relevant and aligned with their business needs. She advises universities and emerging and established life science companies on all aspects of domestic and international patent procurement and enforcement across the biological, biotechnological, agricultural, pharmaceutical and chemical arts. Some of the technologies she works with include mammalian genetics, biological and cell-based therapeutics, small molecules, clinical and research diagnostics, fundamental molecular biology reagents and procedures, and medical devices.

Rita began her law practice at Fitzpatrick, Cella, Harper & Scinto in New York City.

Representative Transactions Include

Rita has secured a number of patents for leading companies, particularly in the biomedical and biotechnology industries.

- U.S. Patent No. 9,204,624: Non-human animals with modified immunoglobulin heavy chain sequences
- U.S. Patent No. 9,113,616: Genetically modified mice having humanized TCR variable genes
- U.S. Patent No. 9,043,996: Genetically modified major histocompatibility complex animals
- U.S. Patent No. 8,796,338: Biguanide compositions and methods of treating metabolic disorders
- U.S. Patent No. 8,871,996: Mice expressing human voltage-gated sodium channels
- U.S. Patent No. 8,735,148: Preserved compositions of activated NK cells and methods of using the same
- U.S. Patent No. 8,722,646: High concentration chitosan-nucleic acid polyplex compositions
- U.S. Patent No. 8,709,417: Combination immunotherapy for the treatment of cancer
- U.S. Patent No. 8,703,485: Germ cells having inactivated endogenous immunoglobulin genes and transgenic animals derived therefrom
- U.S. Patent No. 8,637,308: Method for activating natural killer cells by tumor cell preparation in vitro
- U.S. Patent No. 8,629,108: Rheumatoid arthritis T cell vaccine
- U.S. Patent No. 8,454,891: Disposable laboratory implement
- U.S. Patent No. 7,972,848: Isolation and identification of cross-reactive T cells
- U.S. Patent No. 7,528,240: Methods for producing anti-thymocyte immunoglobulins
- U.S. Patent No. 7,744,893: T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
- U.S. Patent No. 7,671,026: Cytomodulating peptides for treating interstitial cystitis

Presentations

- 103 at the PTO - Presenter, 14th Annual Rocky Mountain Intellectual Property & Technology Institute, Westminster, CO, June 2-3, 2016

Publications

- Untangling the Nanothreads Between the Enablement and Written Description Requirements

- Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma
- Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines
- Comparative analysis of IFN- γ , B7.1, and antisense TGF- β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma
- Construction of new amplifier expression vectors for high levels of IL-2 gene expression